Amarantus BioScience Holdings, Inc.
AMBS · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $23 | $61 | $11 |
| % Growth | -94.5% | -61.8% | 449.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $23 | $61 | $11 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $61 | $95 | $115 | $97 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61 | $95 | $115 | $97 |
| Operating Income | -$60 | -$71 | -$54 | -$86 |
| % Margin | -4,705.9% | -305.5% | -88% | -778.1% |
| Other Income/Exp. Net | $8 | -$1,334 | $390 | -$546 |
| Pre-Tax Income | -$52 | -$1,405 | $336 | -$632 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$52 | -$1,405 | $336 | -$632 |
| % Margin | -4,080.5% | -6,029.9% | 552.2% | -5,704.8% |
| EPS | -0 | -0.002 | 0.001 | -0.001 |
| % Growth | 95.8% | -500% | 154.5% | – |
| EPS Diluted | -0 | -0.002 | 0.001 | -0.001 |
| Weighted Avg Shares Out | 630,407 | 579,607 | 552,107 | 552,107 |
| Weighted Avg Shares Out Dil | 630,407 | 579,607 | 552,107 | 552,107 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $42 | $55 | $27 | $86 |
| EBITDA | -$60 | -$1,351 | $364 | -$546 |
| % Margin | -4,705.9% | -5,794.4% | 596.6% | -4,928.5% |